A team of scientists in Spain has reported a major advance in pancreatic cancer research, one of the most aggressive and deadly forms of cancer. The findings have drawn global attention due to their strong results in preclinical studies.
The research team is led by Mariano Barbacid at the Spanish National Cancer Research Centre. Scientists developed a new triple-combination therapy that fully eliminated pancreatic tumours in laboratory models.
Pancreatic cancer has one of the highest mortality rates among cancers. In advanced stages, survival remains extremely limited. Many cases resist existing treatments, which makes new approaches critical.
🚨ATENÇÃO: Este é Mariano Barbacid, o cientista que pode ter descoberto a cura para o câncer de pâncreas. pic.twitter.com/JRpatjYZh5
— CHOQUEI (@choquei) January 28, 2026According to the researchers, the therapy achieved complete and lasting tumour remission in advanced disease models. These tumours had previously shown resistance to standard treatment options.
The study remains at the preclinical stage. The results do not yet involve human patients. However, experts say the findings mark an important step toward improved treatment strategies.
🚨⚡️A team of scientists in Spain has announced the discovery of a treatment for one of the most aggressive cancers ever (pancreatic cancer), which has a mortality rate of up to 97%.
The Spanish scientist Mariano Barbacid and his team from the "Spanish National Cancer Research… pic.twitter.com/BycOePgNia
— RussiaNews 🇷🇺 (@mog_russEN) January 28, 2026The research team plans to begin human clinical trials in the next phase. These trials will assess safety, dosage, and effectiveness in patients. Regulatory review will follow if trials show positive outcomes.
Scientists caution that many treatments succeed in early testing but fail later. Even so, the results offer renewed hope for patients and researchers working against pancreatic cancer.
Read: Russia’s Enteromix Cancer Vaccine Shows Promise Preclinical Trials
Experts say the study reflects years of focused research on cancer genetics and targeted therapies. They stress that careful testing will determine whether the therapy can translate into a real-world treatment.
